Clinical study for COVID-19 drug development

39 - Biobanques

Service description

Implementation of a regulatory clinical phase for a new drug or repositioning for COVID-19: Phase I for toxicity, Phase IIa or IIb, measurement of efficacy and toxicity on a larger cohort, collection of PK/PD pharmacodynamic data.

It also applies for samples collections that require a specific protocol.

This service is designed for Biotech companies developing SARS-CoV-2 new drugs.

Materials to provide

  • Details about the project

    Further details on the project may be requested.

You will be able to exchange directly with the experts after filling in the form below.

Typical deliverables

  • Study following the specifications validated with the Expert

Get started with your COVID-19 clinical study information request

Please answer the fields below to be contacted by our team of scientists

section1-3
Back
home